Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding ev...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 990
- Institution
- Bristol-Myers Squibb (United States)
External Links
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.